menu search

Moviepass completes seed funding round led by animoca brands to support relaunch of the brand, web 3 initiatives and driving more traffic to theaters

The company will soon be reopening the service for the entire country making it the largest theatrical subscription network; The service is currently ...

January 12, 2023, 4:00 pm

Nurix therapeutics advances promising targeted protein modulation pipeline and outlines 2023 strategic priorities

Nurix leads targeted protein modulation field with its wholly owned clinical stage programs and two strategic collaborations fueled by its DELigase pl...

January 9, 2023, 1:35 pm

Aptose biosciences to present at biotech showcase™ 2023 conference

SAN DIEGO and TORONTO, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company...

December 28, 2022, 7:30 am

Why is athenex (atnx) stock up 44% today?

Athenex (NASDAQ: ATNX ) stock is rocketing higher on Tuesday thanks to positive results from a high-risk early-stage breast cancer clinical trial. The...

December 20, 2022, 12:24 pm

Bcrx stock sinks as biocryst discontinues drug development

BioCryst Pharmaceuticals (NASDAQ: BCRX ) stock is falling on Thursday after revealing the end of development for BCX9930. BCX9930 was in development a...

December 15, 2022, 10:19 am

Biomea fusion announces fda clearance of investigational new drug (ind) application for covalent menin inhibitor bmf-219 in type 2 diabetes

COVALENT-111, a Phase I/II clinical trial in patients with type 2 diabetes, already underway in Canada, will now activate sites in the US As previousl...

December 14, 2022, 9:30 pm

Nurix therapeutics presents positive clinical results from its novel btk degrader (nx-2127) at the 64th american society of hematology (ash) annual meeting

Treatment with NX-2127 provides clinically meaningful responses in heavily pretreated chronic lymphocytic leukemia (CLL) patients regardless of Bruton...

December 12, 2022, 10:30 pm

Kymera therapeutics presents preclinical data demonstrating activity of kt-253, a selective heterobifunctional mdm2 degrader, in acute myeloid leukemia at the american society of hematology annual mee

A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML KT-253 showed combinatorial benefit with BCL...

December 11, 2022, 3:00 pm

Kymera therapeutics presents preclinical data demonstrating activity of kt-253, a selective heterobifunctional mdm2 degrader, in acute myeloid leukemia at the american society of hematology annual mee

A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML KT-253 showed combinatorial benefit with BCL...

December 11, 2022, 3:00 pm

Kymera therapeutics presents preclinical data demonstrating activity of kt-253, a selective heterobifunctional mdm2 degrader, in acute myeloid leukemia at the american society of hematology annual mee

A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML KT-253 showed combinatorial benefit with BCL...

December 11, 2022, 3:00 pm

Kymera therapeutics presents preclinical data demonstrating activity of kt-253, a selective heterobifunctional mdm2 degrader, in acute myeloid leukemia at the american society of hematology annual mee

A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML KT-253 showed combinatorial benefit with BCL...

December 11, 2022, 3:00 pm

Kymera therapeutics presents preclinical data demonstrating activity of kt-253, a selective heterobifunctional mdm2 degrader, in acute myeloid leukemia at the american society of hematology annual mee

A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML KT-253 showed combinatorial benefit with BCL...

December 11, 2022, 3:00 pm

Kura oncology presents updated clinical data from komet-001 trial of menin inhibitor ziftomenib at american society of hematology annual meeting

– 30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML –– Low frequency of differentiation syndrome, including 5% rate ...

December 10, 2022, 3:30 pm

Erasca announces exclusive worldwide license for pan-raf inhibitor naporafenib

Concurrent $100 million equity offering Naporafenib has a potential first-in-class and best-in-class profile in multiple RAS/MAPK pathway-driven tumor...

December 9, 2022, 12:34 pm

Context therapeutics reports encouraging preliminary phase 2 data for ona-xr in metastatic breast cancer

Context Therapeutics (NASDAQ:CNTX) has announced preliminary Phase 2 data from the ongoing SMILE trial of onapristone extended-release (ONA-XR), the c...

December 8, 2022, 8:38 am

Olema oncology announces op-1250 demonstrates attractive combinability with cdk 4/6 inhibitor palbociclib in phase 1b dose escalation study

OP-1250 in combination with palbociclib was well-tolerated in patients with ER+/HER2- breast cancer, with no dose-limiting toxicities, and no observed...

December 7, 2022, 8:37 pm

Revolution medicines: highly differentiated offering gaining traction

Revolution Medicines, Inc. has a highly differentiated portfolio of RAS(ON) and RAS companion inhibitor...

December 7, 2022, 4:35 pm

Hobbiton from the lord of the rings listed on airbnb for $10 nzd per night

Many travellers will have visited the original Hobbiton™ Movie Set for a behind-the-scenes tour, but ...

December 7, 2022, 4:14 am

Adding multimedia mymd pharmaceuticals® to present data on oral tnf-a inhibitor mymd-1® at the british society for immunology (bsi) congress 2022

BALTIMORE--( BUSINESS WIRE )--MyMD Pharmaceuticals, Inc. ® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical compa...

December 6, 2022, 9:40 am

Rapt therapeutics to present flx475 phase 1/2 data at the european society for medical oncology (esmo) immuno-oncology annual congress

SOUTH SAN FRANCISCO, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-s...

November 30, 2022, 7:05 pm


Search within

Pages Search Results: